Source:http://linkedlifedata.com/resource/pubmed/id/16547223
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions |
umls-concept:C0007634,
umls-concept:C0026336,
umls-concept:C0039194,
umls-concept:C0085358,
umls-concept:C0152060,
umls-concept:C0205154,
umls-concept:C0205227,
umls-concept:C0205734,
umls-concept:C0221102,
umls-concept:C0332835,
umls-concept:C0392756,
umls-concept:C1306235,
umls-concept:C1332717,
umls-concept:C1413244,
umls-concept:C1522673,
umls-concept:C1706438,
umls-concept:C1879547,
umls-concept:C2698600
|
pubmed:issue |
7
|
pubmed:dateCreated |
2006-3-20
|
pubmed:abstractText |
The generation of adaptive immune responses is thought to require the presence of adjuvants. Although microbial adjuvants are well characterized, little is known about what provides the adjuvant effect in responses to transplanted cells or in autoimmune diseases. It had been postulated that, in these situations, injured cells instead released "endogenous adjuvants." We previously identified uric acid as an endogenous adjuvant for coinjected Ags. We now report that elimination of uric acid reduced the generation of CTL to an Ag in transplanted syngeneic cells and the proliferation of autoreactive T cells in a transgenic diabetes model. In contrast, uric acid depletion did not reduce the stimulation of T cells to mature APCs or when endogenous APCs were activated with anti-CD40 Ab. These findings support the concept that danger signals contribute to the T cell responses to cell-associated Ags by activating APCs and identify uric acid as one of these signals.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
AIM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Apr
|
pubmed:issn |
0022-1767
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
1
|
pubmed:volume |
176
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
3905-8
|
pubmed:meshHeading |
pubmed-meshheading:16547223-Adjuvants, Immunologic,
pubmed-meshheading:16547223-Adoptive Transfer,
pubmed-meshheading:16547223-Animals,
pubmed-meshheading:16547223-Antigen-Presenting Cells,
pubmed-meshheading:16547223-Antigens,
pubmed-meshheading:16547223-Autoimmunity,
pubmed-meshheading:16547223-CD8-Positive T-Lymphocytes,
pubmed-meshheading:16547223-Cell Differentiation,
pubmed-meshheading:16547223-Cell Line,
pubmed-meshheading:16547223-Cell Proliferation,
pubmed-meshheading:16547223-Diabetes Mellitus, Experimental,
pubmed-meshheading:16547223-Diabetes Mellitus, Type 1,
pubmed-meshheading:16547223-Lymphocyte Activation,
pubmed-meshheading:16547223-Mice,
pubmed-meshheading:16547223-Urate Oxidase,
pubmed-meshheading:16547223-Uric Acid
|
pubmed:year |
2006
|
pubmed:articleTitle |
Cutting edge: elimination of an endogenous adjuvant reduces the activation of CD8 T lymphocytes to transplanted cells and in an autoimmune diabetes model.
|
pubmed:affiliation |
Department of Pathology, University of Massachusetts Medical School, Worcester, 01655, USA.
|
pubmed:publicationType |
Journal Article
|